



EOS imaging Obtains Marketing Approval in South Korea

Paris, October 27, 2014 – EOS imaging (Euronext, FR0011191766 – EOSI), the pioneer in 2D/3D orthopaedic medical imaging, today announced that the Company has received approval from the Korean Food and Drug Administration (KFDA) to market the EOS® system in South Korea, further expanding the Company's commercial opportunities in the fast growing Asia Pacific market. The Company has now obtained authorization to market its technology in 34 countries.

Approval to market the EOS system in South Korea follows similar regional authorizations in Japan and Taiwan and represents a significant milestone as the region continues to adopt EOS' technology for orthopaedic imaging. The KFDA approval will enable the Company to continue expanding its presence in the Asia Pacific medical imaging market, which is predicted to see the highest growth globally during the next 5 years¹.

To develop the Korean market, EOS has established a distribution partnership with DK Medical Solutions (DKMS), a company established in 1986 and specialized in the import and sales of high end medical equipment, in particular imaging equipment.

Marie Meynadier, CEO of EOS imaging, comments on this new authorization: *"This marketing approval in South Korea is yet another great milestone and success for our Company. We are proud to be able to offer our technology in Asia's third largest medical device market and increase our commercial deployment throughout the fast growing Asia Pacific market."*

About EOS imaging:

EOS imaging designs, develops, and markets EOS® and associated solutions, an innovative medical imaging system based on technology that enabled George Charpak to win the Nobel Prize for Physics. The Company is authorized to market in 34 countries, including the United States (FDA), Japan and the European Union (EU). As of December 31, 2013 the Group posted 2013 consolidated revenue of €15.2 million and employed 106 people including an R&D team of 38 engineers. The Group is based in Paris and holds four subsidiaries in Besançon (France), Cambridge (Massachusetts), Montreal (Canada) and Frankfurt (Germany), and offices in Singapore.

EOS imaging is listed on Compartment C of the Euronext Paris
ISIN: FR0011191766 – Ticker: EOSI



Contacts:

Anne Renevot

CFO

Ph: +33 (0)1 55 25 61 24

investors@eos-imaging.com

NewCap

Financial communication and investor relations

Sophie Boulila / Pierre Laurent

Ph: +33 (0)1 44 71 94 91 - eosimaging@newcap.fr

The Ruth Group (US)

Press relations / Calvin Allen

Ph: 646-536-7002

callen@theruthgroup.com

¹ *Medical Imaging Equipment Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013-2019*, Transparency Market Research